Theralase Technologies Inc. (TSXV:TLT)

Theralase Technologies Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1.03	1.07	1.14	0.78	0.93
Revenue Growth (YoY)	-3.45%	-6.00%	45.85%	-15.98%	-3.62%
Cost of Revenue	0.48	0.51	0.51	0.47	0.69
Gross Profit	0.55	0.56	0.63	0.31	0.24
Selling, General & Admin	2.09	2.17	1.58	1.93	2.52
Research & Development	2.75	2.98	4.28	2.92	3.45
Operating Expenses	4.84	5.16	5.86	4.85	5.97
Operating Income	-4.29	-4.59	-5.23	-4.54	-5.72
Interest Expense	-0.02	-0.03	-0.02	-0.01	-0.01
Interest & Investment Income	0.07	0.05	0.03	0.02	0.1
Currency Exchange Gain (Loss)	-0.01	0	-0.03	-0.02	0
EBT Excluding Unusual Items	-4.26	-4.57	-5.25	-4.54	-5.62
Legal Settlements	-	-	0.01	0.13	-
Other Unusual Items	-	-	-	-	0.03
Pretax Income	-4.26	-4.57	-5.24	-4.41	-5.6
Net Income	-4.26	-4.57	-5.24	-4.41	-5.6
Net Income to Common	-4.26	-4.57	-5.24	-4.41	-5.6
Shares Outstanding (Basic)	240	220	208	204	204
Shares Outstanding (Diluted)	240	220	208	204	204
Shares Change (YoY)	9.14%	5.79%	1.79%	-	41.19%
EPS (Basic)	-0.02	-0.02	-0.03	-0.02	-0.03
EPS (Diluted)	-0.02	-0.02	-0.03	-0.02	-0.03
Free Cash Flow	-3.35	-4.11	-5.17	-4.13	-4.61
Free Cash Flow Per Share	-0.01	-0.02	-0.03	-0.02	-0.02
Gross Margin	53.61%	52.52%	55.17%	39.70%	26.24%
Operating Margin	-414.96%	-429.25%	-459.48%	-581.77%	-615.91%
Profit Margin	-411.84%	-427.06%	-459.81%	-565.06%	-602.56%
Free Cash Flow Margin	-323.78%	-384.01%	-454.37%	-529.21%	-496.25%
EBITDA	-4.11	-4.4	-4.99	-4.32	-5.5
D&A For EBITDA	0.18	0.19	0.24	0.22	0.22
EBIT	-4.29	-4.59	-5.23	-4.54	-5.72
Advertising Expenses	0.03	0.02	0.02	0.05	0.08

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.